Mumbai-based Glenmark Pharmaceuticals has introduced Phytonadione Injectable Emulsion USP, 10 mg/mL Single Dose Ampules, in the U.S. market through its subsidiary, Glenmark Pharmaceuticals Inc., USA. This launch expands its institutional channel portfolio and aligns with the company’s strategy of offering quality and affordable alternatives for patients.
Key Details:
- Product Details: The newly launched Phytonadione Injectable Emulsion USP is bioequivalent to Hospira Inc.’s Vitamin K1 Injectable Emulsion USP, 10 mg/mL.
- Market Data: According to IQVIA, the Vitamin K1 Injectable Emulsion market achieved annual sales of approximately $19.7 million for the 12 months ending November 2024.
- Commentary: Marc Kikuchi, President & Business Head for North America, highlighted the company’s focus on enhancing its product range and meeting market demands effectively.
About Glenmark:
Glenmark is a research-driven global pharmaceutical company active in branded, generics, and OTC segments. The company operates in over 80 countries with 11 state-of-the-art manufacturing facilities. Glenmark has also been recognized for its R&D contributions and sustainability initiatives.
